Both serum and tissue Galectin‐1 levels are associated with adverse clinical features in neuroblastoma
Neuroblastoma is one of the most common pediatric solid tumors. Although the 5‐year overall survival rate has increased over the past few decades, high‐risk patients still have a poor prognosis due to a lack of biomonitoring therapy. This study was performed to investigate the role of Galectin‐1 in neuroblastoma biomonitoring therapy. A tissue microarray containing 37 neuroblastoma tissue samples was used to evaluate the correlation between Galectin‐1 expression and clinical features.